diethyl [(1S)-1-{[(2-chloroethyl)(nitroso)carbamoyl]amino}ethyl]phosphonate (BioDeep_00000856723)
代谢物信息卡片
diethyl [(1S)-1-{[(2-chloroethyl)(nitroso)carbamoyl]amino}ethyl]phosphonate
化学式: C9H19ClN3O5P (315.0750804)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC
InChI: InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)/t8-/m0/s1
描述信息
D000970 - Antineoplastic Agents
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- R Stupp, A Tosoni, J E C Bromberg, P Hau, M Campone, J Gijtenbeek, M Frenay, L Breimer, H Wiesinger, A Allgeier, M J van den Bent, U Bogdahn, W van der Graaf, H J Yun, T Gorlia, D Lacombe, A A Brandes. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
Annals of oncology : official journal of the European Society for Medical Oncology.
2011 Sep; 22(9):2144-2149. doi:
10.1093/annonc/mdq729. [PMID: 21321091] - Birute Brasiuniene, V Sokolovas, V Brasiunas, A Barakauskiene, K Strupas. Combined treatment of uveal melanoma liver metastases.
European journal of medical research.
2011 Feb; 16(2):71-5. doi:
10.1186/2047-783x-16-2-71. [PMID: 21463985] - Michele Del Vecchio, Roberta Mortarini, Stefania Canova, Lorenza Di Guardo, Nicola Pimpinelli, Mario R Sertoli, Davide Bedognetti, Paola Queirolo, Paola Morosini, Tania Perrone, Emilio Bajetta, Andrea Anichini. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010 Dec; 16(23):5862-72. doi:
10.1158/1078-0432.ccr-10-2363. [PMID: 21030496] - Chiara Gallo, Carlo Buonerba, Giuseppe Di Lorenzo, Valeria Romeo, Sabino De Placido, Alfredo Marinelli. Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?.
Journal of neuro-oncology.
2010 Nov; 100(2):311-9. doi:
10.1007/s11060-010-0168-y. [PMID: 20556481] - Paolo A Ascierto, Maria Napolitano, Egidio Celentano, Ester Simeone, Giusy Gentilcore, Antonio Daponte, Mariaelena Capone, Corrado Caracò, Rosa Calemma, Gerardo Beneduce, Margherita Cerrone, Vincenzo De Rosa, Giuseppe Palmieri, Giuseppe Castello, John M Kirkwood, Francesco M Marincola, Nicola Mozzillo. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
Journal of translational medicine.
2010 Aug; 8(?):76. doi:
10.1186/1479-5876-8-76. [PMID: 20712892] - Sonia Khier, Carine Deleuze-Masquéfa, Georges Moarbess, Florence Gattacceca, Delphine Margout, Isabelle Solassol, Jean-François Cooper, Frédéric Pinguet, Pierre-Antoine Bonnet, Françoise M M Bressolle. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2010 Jan; 39(1-3):23-9. doi:
10.1016/j.ejps.2009.10.006. [PMID: 19854270] - Seied Mojtaba Valiahdi, Petra Heffeter, Michael A Jakupec, Rodrig Marculescu, Walter Berger, Klemens Rappersberger, Bernhard K Keppler. The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines.
Melanoma research.
2009 Oct; 19(5):283-93. doi:
10.1097/cmr.0b013e32832b272d. [PMID: 19584767] - Martin Loignon, Sylvie Perret, John Kelly, Denise Boulais, Brian Cass, Louis Bisson, Fatemeh Afkhamizarreh, Yves Durocher. Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells.
BMC biotechnology.
2008 Aug; 8(?):65. doi:
10.1186/1472-6750-8-65. [PMID: 18752669] - R Siegel, A Hauschild, C Kettelhack, K C Kähler, A Bembenek, P M Schlag. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
2007 Jun; 33(5):627-32. doi:
10.1016/j.ejso.2006.11.019. [PMID: 17196362] - Charles Stava, Martha Beck, L Todd Weiss, Adriana Lopez, Rena Vassilopoulou-Sellin. Health profiles of 996 melanoma survivors: the M. D. Anderson experience.
BMC cancer.
2006 Apr; 6(?):95. doi:
10.1186/1471-2407-6-95. [PMID: 16620390] - Barbara Fazeny-Dörner, Robert M Mader, Maria Piribauer, Blanka Rizovski, Barbara Stögermaier, Christine Marosi. Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences.
Anti-cancer drugs.
2004 Jun; 15(5):495-8. doi:
. [PMID: 15166624] - A W Tolcher, S L Gerson, L Denis, C Geyer, L A Hammond, A Patnaik, A D Goetz, G Schwartz, T Edwards, L Reyderman, P Statkevich, D L Cutler, E K Rowinsky. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
British journal of cancer.
2003 Apr; 88(7):1004-11. doi:
10.1038/sj.bjc.6600827. [PMID: 12671695] - Jean-Louis Merlin, Sophie Marchal, Carole Ramacci, Maryse Berlion, Marie-Gwenaelle Poullain. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Anti-cancer drugs.
2002 Feb; 13(2):141-7. doi:
10.1097/00001813-200202000-00005. [PMID: 11901306] - N P Vermeulen, J N Commandeur, E J Groot, L W Wormhoudt, S Ramnatshing, Q J Li, J P Brakenhoff. Toxicity of fotemustine in rat hepatocytes and mechanism-based protection against it.
Chemico-biological interactions.
1998 Apr; 110(3):139-58. doi:
10.1016/s0009-2797(98)00004-0. [PMID: 9609383] - C Marzolini, L A Decosterd, F Shen, M Gander, S Leyvraz, J Bauer, T Buclin, J Biollaz, F Lejeune. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Cancer chemotherapy and pharmacology.
1998; 42(6):433-40. doi:
10.1007/s002800050842. [PMID: 9788568] - J T Hartmann, E Schmoll, C Bokemeyer, R Fety, C Lucas, B Giroux, H J Schmoll. Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases.
European journal of cancer (Oxford, England : 1990).
1998 Jan; 34(1):87-91. doi:
10.1016/s0959-8049(97)00359-6. [PMID: 9624243] - J P Brakenhoff, J N Commandeur, L W Wormhoudt, E J Groot, N P Vermeulen. Molecular mechanisms of toxic effects of fotemustine in rat hepatocytes and subcellular rat liver fractions.
Carcinogenesis.
1996 Apr; 17(4):715-24. doi:
10.1093/carcin/17.4.715. [PMID: 8625482] - J P Brakenhoff, J N Commandeur, M H Lamorée, A C Dubelaar, B L van Baar, C Lucas, N P Vermeulen. Identification and quantitative determination of glutathione-related urinary metabolites of fotemustine, a new anti-cancer agent.
Xenobiotica; the fate of foreign compounds in biological systems.
1993 Aug; 23(8):935-47. doi:
10.3109/00498259309059420. [PMID: 8284948] - B Tranchand, C Lucas, P Biron, B Giroux, B Gordon, R Richards, P Solere, N Roux, E Evene, F Mornex. Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas.
Cancer chemotherapy and pharmacology.
1993; 32(1):46-52. doi:
10.1007/bf00685875. [PMID: 8462123] - C Lasset, Y Merrouche, S Negrier, P Rebattu, J Berille, J P Bizzari, F Chauvin, T Philip. Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma.
Cancer chemotherapy and pharmacology.
1993; 32(4):329-31. doi:
10.1007/bf00686182. [PMID: 8324878] - M M Díaz De Guereñu, R J Barrio, A Arranz, J F Arranz. Use of derivatization reactions with adsorptive stripping voltammetry for determining fotemustine in biological samples.
Journal of pharmaceutical and biomedical analysis.
1992 Jul; 10(7):481-6. doi:
10.1016/0731-7085(92)80068-x. [PMID: 1420472] - R Fety, C Lucas, P Solere, V Cour, J Vignoud. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.
Cancer chemotherapy and pharmacology.
1992; 31(2):118-22. doi:
10.1007/bf00685097. [PMID: 1451232] - K U Schallreuter, J M Wood. New aspects in the pathophysiology of cutaneous melanoma: a review of the role of thioproteins and the effect of nitrosoureas.
Melanoma research.
1991 Aug; 1(3):159-67. doi:
NULL. [PMID: 1841712] - I Bartosek, M Corada, S Dallarda, C Lucas, P Deloffre, A Guaitani. Pharmacokinetic profile of fotemustine in rat plasma by electrochemical detection.
Xenobiotica; the fate of foreign compounds in biological systems.
1991 Feb; 21(2):235-42. doi:
10.3109/00498259109039465. [PMID: 2058178] - A Guaitani, M Corada, C Lucas, A Lemoine, S Garattini, I Bartosek. Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma.
Cancer chemotherapy and pharmacology.
1991; 28(4):293-7. doi:
10.1007/bf00685537. [PMID: 1879046] - K U Schallreuter, J M Wood, H Mensing, E W Breitbart. Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine.
Cancer chemotherapy and pharmacology.
1991; 29(2):167-71. doi:
10.1007/bf00687330. [PMID: 1760862] - R M Ings, M Breen, K Devereux, A J Gray, F E Edwards, C Lucas, M Briggs, B V Robinson, D B Campbell. The comparative disposition of [14C]-fotemustine in non-tumourous and tumourous mice.
Cancer chemotherapy and pharmacology.
1990; 27(2):106-10. doi:
10.1007/bf00689092. [PMID: 2249325] - R M Ings, A J Gray, A R Taylor, B H Gordon, M Breen, M Hiley, R Brownsill, N Marchant, R Richards, D Wallace. Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients.
European journal of cancer (Oxford, England : 1990).
1990; 26(7):838-42. doi:
10.1016/0277-5379(90)90166-q. [PMID: 2145908] - G Deray, D Khayat, C Jacquiaud, J P Bizzari, R Bourbouze, L Musset, M C Jaudon, B Baumelou, C Jacquillat, C Jacobs. Renal effects of S10036 in man.
Cancer chemotherapy and pharmacology.
1990; 26(6):467-8. doi:
10.1007/bf02994102. [PMID: 2225319] - J A Boutin, K Norbeck, P Moldeus, A Genton, M Paraire, J P Bizzari, G Lavielle, C A Cudennec. Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes.
European journal of cancer & clinical oncology.
1989 Sep; 25(9):1311-6. doi:
10.1016/0277-5379(89)90078-3. [PMID: 2806354] - B H Gordon, R P Richards, M P Hiley, A J Gray, R M Ings, D B Campbell. A new method for the measurement of nitrosoureas in plasma: an h.p.l.c. procedure for the measurement of fotemustine kinetics.
Xenobiotica; the fate of foreign compounds in biological systems.
1989 Mar; 19(3):329-39. doi:
10.3109/00498258909042277. [PMID: 2665327]